Author(s):
Snehal L. Bornare, Bhakti P. Patil, Ankita R. Pawar, Gajanan B. Raut, Srushti V. Saindar, Swarup G. Salunke
Email(s):
swarupsalunke004@gmail.com
DOI:
10.52711/0975-4377.2026.00023 
Address:
Snehal L. Bornare1, Bhakti P. Patil2, Ankita R. Pawar2, Gajanan B. Raut2, Srushti V. Saindar2, Swarup G. Salunke2
1Assistant Professor, Department of Pharmaceutics, Pravara Rural College of Pharmacy, Loni, Maharashtra, India.
2Bachelor of Pharmacy Students, Pravara Rural College of Pharmacy, Loni, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 18,
Issue - 2,
Year - 2026
ABSTRACT:
Quality by Design (QbD) has arisen as a scientific and risk-oriented methodology for pharmaceutical development, serving as a bridge between industry and regulatory agencies to ensure consistent product quality. In contrast to conventional quality testing, Quality by Design (QbD) emphasizes the integration of quality into formulations and production processes from the outset. This methodology focuses on delineating the Target Product Profile (TPP) and Target Product Quality Profile (TPQP), identifying Critical Quality Attributes (CQAs), and evaluating the influence of Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) on product efficacy. The incorporation of design space, control strategy, and risk assessment tools into product lifecycle management facilitates ongoing enhancement. QbD, which has its roots in ICH guidelines Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System), improves process comprehension, permits regulatory flexibility, lessens validation burdens, and minimises post-approval modifications. Through the use of instruments like Process Analytical Technology (PAT) and Design of Experiments (DoE), QbD guarantees reliable product development and facilitates quicker regulatory approvals. All things considered, QbD is a contemporary paradigm in pharmaceutical sciences that promotes creativity, dependability, and regulatory compliance in the creation and production of new drugs.
Cite this article:
Snehal L. Bornare, Bhakti P. Patil, Ankita R. Pawar, Gajanan B. Raut, Srushti V. Saindar, Swarup G. Salunke. A Review on Quality by Design. Research Journal of Pharmaceutical Dosage Forms and Technology. 2026; 18(2):147-4. doi: 10.52711/0975-4377.2026.00023
Cite(Electronic):
Snehal L. Bornare, Bhakti P. Patil, Ankita R. Pawar, Gajanan B. Raut, Srushti V. Saindar, Swarup G. Salunke. A Review on Quality by Design. Research Journal of Pharmaceutical Dosage Forms and Technology. 2026; 18(2):147-4. doi: 10.52711/0975-4377.2026.00023 Available on: https://rjpdft.com/AbstractView.aspx?PID=2026-18-2-9
REFERENCES:
1. Woodcock J. The concept of pharmaceutical quality. American Pharmaceutical Review. 2004; 7(6): 10–15.
2. Lionberger R.A., Lee S.L., Lee L., Raw A., Yu L.X. Quality by Design: Concepts for ANDAs. The AAPS Journal. 2008; 10(2): 268–276.
3. Yu L.X. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control. Pharmaceutical Research. 2008; 25:781–791.
4. Rathore A.S. Roadmap for Implementation of Quality by Design (QbD) for Biotechnology Products. Trends in Biotechnology. 2005; 27: 546–553.
5. Rathore A.S., Winkle H. Quality by Design for Biopharmaceuticals. Nature Biotechnology. 2009; 27: 26–34.
6. Nadpara N.P., Thumar R.V., Kalola V.N., Patel P.B. Quality by Design (QbD): A Complete Review. International Journal of Pharmaceutical Sciences Review and Research. 2012; 17(2): 20–28.
7. Gupta A., Fuloria N.K. Short Review on Quality by Design: A New Era of Pharmaceutical Drug Development. International Journal of Drug Development & Research. 2012; 4(3): 19–26.
8. Patil A.S., Pethe A.M. Quality by Design (QbD): A New Concept for Development of Quality Pharmaceuticals. International Journal of Pharmaceutical Quality Assurance. 2013; 4(2): 13–19.
9. Kumar V.P., Gupta N.V. A Review on Quality by Design Approach (QbD) for Pharmaceuticals. International Journal of Drug Development & Research. 2015; 7(1): 52–60.
10. Roy S. Quality by Design: A Holistic Concept of Building Quality in Pharmaceuticals. International Journal of Pharmaceutical and Biomedical Research. 2012; 3(2): 100–108.
11. Purohit P.J., Shah K.V. Quality by Design (QbD): New Parameter for Quality Improvement & Pharmaceutical Drug Development. Pharma Science Monitor: International Journal of Pharmaceutical Sciences. 2013; 4(3): 1–19.
12. Nwoko V.E. Quality by Design (QbD): Manufacturing and Product Quality of Generic Drugs Perspective. Journal of Global Trends in Pharmaceutical Sciences. 2013; 4(3): 1257–1262.
13. Jain S. Quality by Design (QbD): A Comprehensive Understanding of Implementation and Challenges in Pharmaceutical Development. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 6(1): 29–35.
14. Trivedi B. Quality by Design (QbD) in Pharmaceuticals. International Journal of Pharmacy and Pharmaceutical Sciences. 2012; 4(3): 17–29.
15. Drakulich A. Critical Challenges to Implementing QbD: A Q&A with FDA. Pharmaceutical Technology. 2009; 33: 90–94.
16. Bhattacharya J. Quality Risk Management – Understanding and Control of Risk in Pharmaceutical Manufacturing Industry. International Journal of Pharmaceutical Science Invention. 2015; 4(3): 29–41.
17. Chowdary K.P.R., Ravi Shankar K., Kumar P.S. Recent Research on QbD Approach in Formulation Development – A Review. International Journal of Chemical Science and Technology. 2014; 4(4): 282–292.
18. Altan S., Bergum J., Pfahler L., Senderak E., Sethuraman S., Vukovinsky K.E. Statistical Considerations in Design Space Development (Part I). Pharmaceutical Technology. 2010; 34: 66–70.
19. Altan S., Bergum J., Pfahler L., Senderak E., Sethuraman S., Vukovinsky K.E. Statistical Considerations in Design Space Development (Part II). Pharmaceutical Technology. 2010; 34: 52–60.
20. Wu H., White M., Khan M.A. Quality-by-Design (QbD): An Integrated Process Analytical Technology (PAT) Approach for a Dynamic Pharmaceutical Co-precipitation Process Characterization and Process Design Space Development. International Journal of Pharmaceutics. 2011; 405: 63–78.
21. Looby M., Ibarra N., Pierce J.J., Buckley K., O'Donovan E., Heenan M. Application of Quality by Design Principles to the Development and Technology Transfer of a Major Process Improvement for the Manufacture of a Recombinant Protein. Biotechnology Progress. 2011; 27: 1718–1729.
22. Callis J.B., Illman D.L., Kowalski B.R. Process Analytical Chemistry. Analytical Chemistry. 1987; 59: 624A–637A.
23. Munson J., Gujral B., Stanfield C.F. A Review of Process Analytical Technology (PAT) in the U.S. Pharmaceutical Industry. Current Pharmaceutical Analysis. 2006; 2: 405–414.
24. Leuenberger H., Puchkov M., Krausbauer E., Betz G. Manufacturing Pharmaceutical Granules: Is the Granulation End-point a Myth? Powder Technology. 2009; 189: 141–148.
25. Zhang H., Lawrence X. Dissolution Testing for Solid Oral Drug Products: Theoretical Considerations. American Pharmaceutical Review. 2004; 26–31.
26. Gawade A., Chemate S., Kuchekar A. Pharmaceutical Quality by Design: A New Approach in Product Development. Research & Reviews: Journal of Pharmacy and Pharmaceutical Sciences. 2013; 2(3): 5–12.
27. Elliott P., Billingham S., Bi J., Zhang H. Quality by Design for Biopharmaceuticals: A Historical Review and Guide for Implementation. Pharmaceutical Bioprocessing. 2013; 1:105–122.
28. Gandhi A, Roy C; Quality by Design (QbD) in Pharmaceutical Industry: Tools, Perspectives and Challenges; PharmaTutor; 2016; 4(11); 12-20
29. Jadhav, J.B. et al Int. J. Pure App. Biosci. 2014; 2(5): 214-223
30. Juran J.M. Juran on Quality by Design: The New Steps for Planning Quality into Goods and Services. Revised Edition. Free Press, New York;1992.
31. Ian House. Process Understanding: For Scale-up and Manufacturing Method of Active Ingredients. 1st ed. Wiley-VCH Verlag GmbH & Co. KGaA;2011
32. FDA Guidance for Industry and Review Staff: Target Product Profile – A Strategic Development Process Tool (Draft Guidance). U.S. FDA.
33. FDA Guidance for Industry: PAT – A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance. U.S. FDA, Washington, DC, USA; 2004.
34. FDA: Pharmaceutical Quality for the 21st Century – A Risk-Based Approach (Progress Report).2007.
35. FDA, Office of Generic Drugs. White Paper on Question-Based Review (QbR). [Available at: http://www.fda.gov/cder/OGD/QbR.htm]
36. Nasr M. FDA’s Quality Initiatives: An Update. [Available at: http://www.gmpcompliance.com/daten/download/FDAs_Quality_Initiative.pdf]
37. IBM Business Consulting Services. Transforming Industrialization: A New Paradigm for Pharmaceutical Development. [Available at: www-935.ibm.com/services/us/imc/pdf/ge510-3997-transforming-industrialization.pdf]
38. FDA: Pharmaceutical Quality for the 21st Century: A Risk-Based Approach Progress Report. [Available at: http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4228m1.pdf]